Aldosterone Blockade in Patients with Chronic Heart Failure

Cardiology Clinics

Volumn 26, Issue 1, 2008, Pages 15-21

  Pitt, Bertram ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; NITRIC OXIDE; PLACEBO; POTASSIUM; SPIRONOLACTONE;

ADD ON THERAPY; ATHEROSCLEROSIS; CLINICAL STUDY; CLINICAL TRIAL; COMORBIDITY; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INHIBITION; DRUG TARGETING; ENDOTHELIUM; GYNECOMASTIA; HEALTH CARE ORGANIZATION; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE INJURY; HEART VENTRICLE REMODELING; HORMONE INHIBITION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MASTALGIA; MENSTRUAL IRREGULARITY; MORTALITY; NEW YORK HEART ASSOCIATION; POLYPHARMACY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; VASODILATATION;

ALDOSTERONE; HEART FAILURE; HUMANS;

EID: 39649119493     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2007.12.016     Document Type: Review

References (48)

1. McKelvie R.S., Yusuf S., Pericak D., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 100 10 (1999) 1056-1064
2. Okubo S., Niimura F., Nishimura H., et al. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest 99 5 (1997) 855-860
3. Milliez P., Deangelis N., Rucker-Martin C., et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 26 20 (2005) 2193-2199
4. Mosso L.M., Carvajal C.A., Maiz A., et al. A possible association between primary aldosteronism and a lower beta-cell function. J Hypertens 25 10 (2007) 2125-2130
5. Hitomi H., Kiyomoto H., Nishiyama A., et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 50 4 (2007) 750-755
6. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 10 (1999) 709-717
7. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 22 (2001) 1651-1658
8. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 14 (2003) 1309-1321
9. Hunt S.A. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 6 (2005) e1-e82
10. Nieminen M.S., Bohm M., Cowie M.R., et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 26 4 (2005) 384-416
11. Berry C., and McMurray J.J. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart 85 4 (2001) E8
12. Schepkens H., Vanholder R., Billiouw J.M., et al. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 110 6 (2001) 438-441
13. Svensson M., Gustafsson F., Galatius S., et al. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. BMJ 327 7424 (2003) 1141-1142
14. Juurlink D.N., Mamdani M.M., Lee D.S., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 6 (2004) 543-551
15. Shah K.B., Rao K., Sawyer R., et al. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol 46 5 (2005) 845-849
16. Pitt B., White H., Nicolau J., et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 46 3 (2005) 425-431
17. Steg P.G., Dabbous O.H., Feldman L.J., et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 109 4 (2004) 494-499
18. Holnloser S., Kuck K., Dorian P., et al. The DINAMIT investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351 (2004) 2481-2488
19. Zannad, Adamopoulos, Fay, et al. P484: how early should eplerenone be initiated in acute myocardial infarction complicated by heart failure? An analysis of early vs. initiation in the EPHESUS trial. [abstract]. Eur Heart J 28 (2007) 52
20. Hayashi M., Tsutamoto T., Wada A., et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 107 20 (2003) 2559-2565
21. Banas J, Krum H, Corbalan R, et al. Impact of eplerenone on blood pressure in post-acute myocardial infarction patients with heart failure and left ventricular systolic dysfunction: results from EPHESUS. Submitted for publication.
22. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 20 (2003) 1893-1906
23. Pitt B., Krum H., Nicolau J., et al. The EPHESUS trial: effect of eplerenone in patients with a baseline history of hypertension. Circulation 108 Suppl (2003) 599
24. Pitt B., Reichek N., Willenbrock R., et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108 15 (2003) 1831-1838
25. Zannad F., Alla F., Dousset B., et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 102 22 (2000) 2700-2706
26. Lacolley P., Labat C., Pujol A., et al. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 106 22 (2002) 2848-2853
27. Fraccarollo D., Galuppo P., Hildemann S., et al. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 42 9 (2003) 1666-1673
28. McMurray J, Pitt B, Latini R. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. To be presented at the ESC 9/2007. Lancet, in press.
29. Pitt B., McMurray J., Latini R., et al. Neurohumoral effects of a new oral direct renin inhibitor in stable heart failure: the Aliskiren Observation of Heart Failure Treatment Study (ALOFT). Circulation 116 16 (2007) II-549
30. Kasama S., Toyama T., Kumakura H., et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 41 4 (2003) 574-581
31. Cittadini A., Monti M.G., Isgaard J., et al. Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure. Cardiovasc Res 58 3 (2003) 555-564
32. Chan A.K., Sanderson J.E., Wang T., et al. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. J Am Coll Cardiol 50 7 (2007) 591-596
33. Aldosterone antagonist therapy for adults with heart failure and preserved systolic function. Available at: http://www.clinicaltrials.gov. 2007.
34. Costello-Boerrigter L.C., Boerrigter G., Harty G.J., et al. Mineralocorticoid escape by the kidney but not the heart in experimental asymptomatic left ventricular dysfunction. Hypertension 50 3 (2007) 481-488
35. Mottram P.M., Haluska B., Leano R., et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110 5 (2004) 558-565
36. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 9386 (2003) 777-781
37. Carson P., Massie B.M., McKelvie R., et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail 11 8 (2005) 576-585
38. Yoshida M., Ma J., Tomita T., et al. Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure. Congest Heart Fail 11 1 (2005) 12-16
39. Lalevee N., Rebsamen M.C., Barrere-Lemaire S., et al. Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc Res 67 2 (2005) 216-224
40. Perrier E., Kerfant B.G., Lalevee N., et al. Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction. Circulation 110 7 (2004) 776-783
41. Leopold J.A., Dam A., Maron B.A., et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 13 2 (2007) 189-197
42. Kobayashi N., Yoshida K., Nakano S., et al. Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension 47 4 (2006) 671-679
43. Bauersachs J., Heck M., Fraccarollo D., et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 39 2 (2002) 351-358
44. Rajagopalan S., Duquaine D., King S., et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105 18 (2002) 2212-2216
45. Struthers A. Impact of aldosterone on vascular pathophysiology. Congest Heart Fail 8 (2002) 18-22
46. Takai S., Jin D., Muramatsu M., et al. Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension 46 5 (2005) 1135-1139
47. Schiffrin E.L. Effects of aldosterone on the vasculature. Hypertension 47 3 (2006) 312-318
48. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 3 (2000) 145-153